Fatty liver drug trial in HIV patients stalls after enrolling just 4 people

NCT ID NCT05211284

Terminated Disease control Sponsor: Zydus Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaningful results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Saroglitazar magnesium
What this could lead to: If it works, this could point toward a treatment for fatty liver disease in people living with HIV.
What could go wrong: This was a very small, early-phase trial that was terminated early with only 4 participants. Results are not available, so we cannot draw any conclusions about safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

Zydus US001

Durham, North Carolina, 27710, United States
Zydus US002

Indianapolis, Indiana, 46202, United States
Zydus US003

Baltimore, Maryland, 21287, United States
Zydus US004

Birmingham, Alabama, 35294-2050, United States
Zydus US005

La Jolla, California, 92037, United States
Zydus US006

San Francisco, California, 94143, United States
Zydus US007

Houston, Texas, 77030, United States
Zydus US008

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.